Loading...
Market
What will be Autolus' revenue growth rate in 2025 post-Aucatzyl approval?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Annual financial reports of Autolus Therapeutics
Story
FDA Approves Autolus Therapeutics' Aucatzyl for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Under FELIX Program
Nov 8, 2024, 09:24 PM
The U.S. Food and Drug Administration (FDA) has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel – obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This approval, part of the FELIX program, marks a significant milestone for the company and provides a new treatment option for patients suffering from this aggressive form of leukemia. Despite earlier rumors and a temporary dip in share prices, the official announcement has confirmed the FDA's decision, which is expected to positively impact Autolus Therapeutics' market position.
View original story
Similar markets
Partnership with a pharmaceutical company • 33%
Acquisition by another company • 33%
No partnership or acquisition • 34%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%